Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.44 USD
+0.11 (1.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.43 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Tango Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 37 | 25 | 37 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 37 | 25 | 37 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 151 | 136 | 95 | 0 | 0 |
Income After Depreciation & Amortization | -114 | -111 | -58 | 0 | 0 |
Non-Operating Income | 13 | 3 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -102 | -108 | -58 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -102 | -108 | -58 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -102 | -108 | -58 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -115 | -109 | -57 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 2 | 1 | 0 | NA |
Income After Depreciation & Amortization | -114 | -111 | -58 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 94.57 | 87.82 | 62.11 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.08 | -1.23 | -0.94 | NA | NA |
Diluted Net EPS (GAAP) | -1.08 | -1.23 | -0.94 | -0.04 | NA |
Fiscal Year end for Tango Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 5.43 | 10.73 | 14.60 | 5.77 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.43 | 10.73 | 14.60 | 5.77 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 40.45 | 36.36 | 37.84 | 36.05 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -35.02 | -25.63 | -23.24 | -30.28 |
Non-Operating Income | NA | 4.30 | 3.39 | 2.60 | 2.28 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -30.72 | -22.24 | -20.65 | -28.01 |
Income Taxes | NA | 0.05 | 0.02 | 0.06 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -30.76 | -22.26 | -20.71 | -28.01 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -30.76 | -22.26 | -20.71 | -28.01 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 97.22 | 97.03 | 88.36 | 88.19 |
Diluted EPS Before Non-Recurring Items | NA | -0.32 | -0.23 | -0.23 | -0.32 |
Diluted Net EPS (GAAP) | NA | -0.30 | -0.23 | -0.23 | -0.32 |